etc-1002 and Aortic-Diseases

Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. In phase 2 studies, BemA lowers elevated low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients. In the present study, we tested the ability of BemA to decrease plasma cholesterol and LDL-C and attenuate atherosclerosis in a large animal model of familial hypercholesterolemia.. Gene targeting has been used to generate Yucatan miniature pigs heterozygous (. In a large animal model of LDLR deficiency and atherosclerosis, long-term treatment with BemA reduces LDL-C and attenuates the development of aortic and coronary atherosclerosis in both

Topics: Animals; Animals, Genetically Modified; Anticholesteremic Agents; Aortic Diseases; Atherosclerosis; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Dicarboxylic Acids; Disease Models, Animal; Down-Regulation; Fatty Acids; Female; Gene Expression Regulation; Genetic Predisposition to Disease; Hyperlipoproteinemia Type II; Male; Phenotype; Plaque, Atherosclerotic; Receptors, LDL; Swine; Swine, Miniature